| Celso Arango|
| Schizophrenia: Time to Commit to Policy Change|
University of Oviedo, Complutense University of Madrid
Celso Arango Wikipedia
Celso Arango (Palma de Mallorca 1968- ) is a Spanish psychiatrist.
After completing his medical studies at the University of Oviedo in Spain and Manchester University in the UK (1992), he received his PhD in Psychiatry from the Universidad Complutense of Madrid (1998). He did a Residency in Psychiatry at Hospital General Universitario Gregorio Marañón in Madrid (1993-1997), followed by a Research Fellowship at the University of Maryland School of Medicine in Baltimore.
Dr. Arango is currently Head of the Child and Adolescent Psychiatry Service at Hospital General Universitario Gregorio Marañón. He is also an Adjunct Professor of Psychiatry at the University of Maryland in Baltimore, a Full Professor of Psychiatry at the Universidad Complutense in Madrid and Full Adjunt Professor of Psychiatry at University of California, San Francisco (UCSF).
In 2008 he was awarded the Spanish Ministry of Health Medal of Honor, the “Cruz de la Orden Civil de Sanidad”. Between 2012 and 2014, he was the Fundación Alicia Koplowitz Endowed Chair for Child and Adolescent Psychiatry at the Universidad Complutense, and since 2013 is member of the European Brain Council Board (European Commission's Advisory council). Since 2014 is President of the National Commission of the Child and Adolescent Psychiatry specialty of the Ministry of Health, Social Services and Equality.
Since 2016 is President of The European College of Neuropsychopharmacology (ECNP).
Dr. Arango has been from 2008 to 2016 the Scientific Director of the Spanish Psychiatric Research Network (CIBERSAM), with 23 centers and more than 400 researchers. He is also Coordinator of the Child and Adolescent First-Episode Psychosis Study (CAFEPS) funded by the Spanish Ministry of Health (with eight centers in Spain) and the Child and Adolescent Neuropsychiatry Network funded by the European College of Neuropsychopharmacology (ECNP).
He has participated in more than 71 competitively funded research projects, as Principal Investigator in 55 of them, including projects with international funding (Stanley Foundation, NARSAD, NIMH, European Commission, etc.) and several clinical drug trials. He is also the coordinator of several multicenter projects assessing multiple prognostic factors and treatment in early-onset psychosis, and is currently participating in eight EU projects funded by the VII Framework Programmes for Research and Technological Development.
Dr. Arango has written more than 300 peer-reviewed articles, 7 books, and more than 44 book chapters. Many of his articles and book chapters have focused on the neurobiology of early-onset and first-episode psychoses, as well as the safety of psychiatric medications in pediatric patients. In addition, his group has shown how patients with a first psychotic episode experience greater losses of gray matter than expected and has demonstrated a correlation of gray matter loss with antioxidant status.Gallinget al. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry, 73(3):247-59, 2016.
Vorstman JA, et al. Deletion Syndrome. Cognitive Decline Preceding the Onset of Psychosis in Patients with 22q11.2 Deletion Syndrome. JAMA Psychiatry, 72(4):377-85, 2015.
Steinberg S, et al. Common variant at 16p11.2 conferring risk of psychosis. Molecular Psychiatry. 2014 Jan;19(1):108-14.
Arango C. Child neuropsychopharmacology: good news… the glass is half full. World Psychiatry. 2013 Jun;12(2):128-9.
Arango C et al. Progressive brain changes in children and adolescents with first-episode psychosis. JAMA Psychiatry. 2012 Jan; 69(1):16-26.
Steinberg S et al. Common Variants at VRK2 and TCF4 Conferring Risk of Schizophrenia. Hum Mol Genet. 2011 Oct; 20(20):4076-81.
Arango C et al. Lessons learned about poor insight. Schizophr Bull. 2011 Jan; 37(1):27-8.
Arango C. Attenuated psychotic symptoms syndrome: how it may affect child and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2011 Feb; 20(2): 67-70.
Janssen J et al. Gyral and sulcal cortical thinning in adolescents with first episode early-onset psychosis. Biol Psychiatry. 2009 Dec 1;66(11):1047-54.
Vitiello B et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009 Sep;19(9):629-35.